Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
Interventions: Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine, 5-Fluorouracil, Docetaxel, Nutrition questionnaires (optional), stool and saliva samples (optional); Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more

Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • Denver, Colorado + 16 more

Conditions: Breastfeeding, Preterm Birth, Breast Pumping, Lactation; Insufficient, Partial
Interventions: point-of-care milk sodium testing; Diagnostic Test
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HRCT, Blood Draw; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years to 101 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis, Laryngeal Papilloma, Recurrent, Human Papilloma Virus
Interventions: M7824; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Necrotizing Soft Tissue Infections
Interventions: Not listed
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Lubbock, Texas

Conditions: Heart Diseases, Cardiovascular Diseases
Interventions: Dr. Dean Ornish Program for Reversing Heart Disease; Behavioral
Lead sponsor: Windber Research Institute; Other
Eligibility: 21 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Windber, Pennsylvania

Conditions: Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
Interventions: Phlebotomy; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 22 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE)
Interventions: Not listed
Lead sponsor: Center Trials & Treatment; Other
Eligibility: 18 Years and older
Enrollment: 2,432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Jacksonville, Florida • Ocala, Florida • Charleston, South Carolina + 1 more

Conditions: Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
Interventions: UCN-01 (7-hydroxystaurosporine); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Genetic Polymorphism
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
Interventions: Enzalutamide, Ribociclib, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biopsy, Echocardiography, Multigated Acquisition Scan, Bone Scan, Computed Tomography, Magnetic Resonance Imaging; Drug · Other · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more

Conditions: Cystic Fibrosis
Interventions: digitoxin, placebo; Drug · Other
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
Interventions: SGN-35; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteopathic Manipulation, Low Back Pain, Biomarkers
Interventions: The Osteopathic Manipulation; Other
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 20 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Colorectal Cancer
Interventions: Obinutuzumab, Atezolizumab, Cibisatamab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Los Angeles, California • Santa Monica, California • Stanford, California + 4 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Group 1, Group 2; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatocellular Carcinoma (HCC), Solid Malignancies
Interventions: FGF401, PDR001; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions: A2B694, A2B543, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions: AVP-923; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 39
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more

Conditions: Lung Cancer
Interventions: Biomarker (not used as an intervention); Device
Lead sponsor: Allegro Diagnostics, Corp.; Industry
Eligibility: 21 Years and older
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 17 more

Conditions: Colorectal Cancer
Interventions: capecitabine, 5-fluorouracil, Surgical Resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Sodium Awareness in Lactation Trial

The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

M7824 in People With Recurrent Respiratory Papillomatosis

RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections

Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal

Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase II Study of Digitoxin to Treat Cystic Fibrosis

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Airway Epithelium Gene Expression: AEGIS IDE

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy